| Oct 31 |
Eylea headwinds said to be behind Regeneron’s post-Q3 plunge
|
| Oct 31 |
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
|
| Oct 31 |
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
Regeneron down 10% despite top and bottom line beats
|
| Oct 31 |
Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom
|
| Oct 31 |
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
| Oct 31 |
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
|
| Oct 31 |
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
|
| Oct 31 |
Regeneron beats results estimates on demand for eczema treatment, eye drug
|
| Oct 31 |
Regeneron: Q3 Earnings Snapshot
|
